Medication

A medication is a substance taken to treat, prevent, or manage a medical condition — whether obtained by prescription or bought without one. The category spans antidepressants, antiepileptics, antihypertensives, antihistamines, hormonal preparations, pain relievers, and many others.

Medications matter in a harm-reduction context because they form part of a person's pharmacological baseline on any given day. Whatever someone takes regularly, their enzyme activity, receptor occupancy, and neurotransmitter levels already reflect it. A psychoactive substance enters a body already shaped by those effects.

Unlike most unregulated compounds, medications carry documented pharmacology: studied mechanisms, known metabolic pathways, and recorded interactions. That documentation is a resource — but its scope is narrower than it appears.

How it is done

Accounting for medications in harm-reduction practice starts with disclosure: listing everything taken regularly, not only prescription items. Over-the-counter drugs, supplements, hormonal contraceptives, and herbal extracts are frequently overlooked but pharmacologically active. Many interact with psychoactive compounds in ways that are not immediately obvious from the product label.

The next step is checking that list against reliable interaction resources before combining substances. Interaction databases draw on clinical pharmacology literature and flag enzyme-level competition, receptor overlap, and known adverse pairings. Medications that inhibit or induce CYP enzymes — the liver enzyme family responsible for metabolising many substances — are especially relevant, because they alter how quickly other compounds clear the body.

For medications requiring stable blood levels — anticoagulants, mood stabilisers, immunosuppressants — any new substance is a potential source of interference. Some also carry risks around abrupt discontinuation, which is worth noting when a substance might disrupt a regular schedule.

What it cannot tell you

Documented pharmacology covers what has been studied, not everything that is true. The absence of a listed interaction between a medication and a psychoactive substance most often means the combination has not been formally studied — not that no interaction exists. The literature is densest around clinically common drug pairings; novel or unscheduled substances rarely appear in it.

Individual pharmacogenetics introduces a further gap. Enzyme variants — particularly in the CYP2D6 pathway — make some people substantially faster or slower metabolisers of specific compounds. A combination characterised as mild at the population level may behave very differently in a given person, without any prior indication that it will.

Over-the-counter status is a common source of misplaced confidence. It reflects a regulatory judgment about risk under standard use conditions, not a statement about safety in combination with psychoactive substances. Sedating antihistamines, for instance, have additive effects with central nervous system depressants; that activity does not disappear because the drug is sold without a prescription.

The most consequential blind spot is interaction directionality: documentation tends to describe what a medication does to other substances, less often what other substances do to the medication itself — altering its absorption, its effective concentration, or the window during which it works.